CKD Bio Corp.
Financials
Valuation Metrics
CKD Bio Corp.'s Market Cap is ₩700B. At end of 2025 it was ₩1116B. Ranked #1543 of 2,421 in KR market (top 64%), #637 of 781 on KOSPI (top 82%), #169 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 73%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 70.00B KRW | KR#1,543/2,421 Sec#169/231 |
| Revenue | 158.12B KRW | KR#1,146/2,421 Sec#69/231 |
| Net Income | -10.74B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 293.05B KRW | KR#1,053/2,421 Sec#71/231 |
| Net Assets | 119.57B KRW | KR#1,292/2,421 Sec#100/231 |
| Employees | 509 | KR#490/2,421 Sec#41/231 |
| Value | ||
| P/B | 0.59x | KR#960/2,421 Sec#50/231 |
| P/S | 0.44x | KR#835/2,421 Sec#33/231 |
| FCF Yield | -15.64% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -8.98% | KR#1,919/2,421 Sec#142/231 |
| ROA | -3.67% | KR#1,868/2,421 Sec#132/231 |
| Op. Margin | -5.10% | KR#1,859/2,421 Sec#124/231 |
| Revenue Growth | -0.58% | KR#1,563/2,421 Sec#155/231 |
| Earnings Growth | -669.88% | KR#1,313/2,421 Sec#92/231 |
| Financial Health | ||
| Debt Ratio | 145.09% | KR#1,876/2,421 Sec#207/231 |
| Total Debt | 146.35B KRW | KR#611/2,421 Sec#34/231 |
| FCF | -10.95B KRW | KR#1,737/2,421 Sec#153/231 |
| Cash | 517.3M KRW | KR#2,362/2,421 Sec#224/231 |
| Current Ratio | 1.06x | KR#1,660/2,421 Sec#165/231 |
| Dividend | ||
| Div. Yield | 1.57% | KR#985/2,421 Sec#53/231 |
| Div. Growth | -0.00% | KR—/2,421 Sec—/231 |
| Performance | ||
| 1Y Return | -46.61% | KR#1,981/2,421 Sec#174/231 |
| 1M Return | -8.00% | KR#1,999/2,421 Sec#165/231 |
| From 52W High | -48.76% | KR#1,332/2,421 Sec#102/231 |
| 1Y MDD | -50.20% | KR#1,002/2,421 Sec#83/231 |
| Trading | ||
| Volume | 4,297 shares | KR#2,155/2,421 Sec#206/231 |
| Trading Value | 54.7M KRW | KR#1,801/2,421 Sec#185/231 |
| Foreign Own. | 1.43% | KR#1,852/2,421 Sec#183/231 |
| Per Share | ||
| EPS | -1,958 KRW | KR—/2,421 Sec—/231 |
| BPS | 21,796 KRW | KR#503/2,421 Sec#36/231 |
Company Info
Chong Kun Dang Bio was established in 2001 through a spin-off of the fermentation and refined raw materials business. It supplies over 30 types of active pharmaceutical ingredients (APIs), including antibiotics, to over 50 countries worldwide using advanced fermentation facilities. The company produces probiotic raw materials and finished products with its fermentation and patented technologies, and has launched botulinum toxin products from a dedicated plant in Osong. Chong Kun Dang Bio is focusing on obtaining patents for regulatory market entry, achieving cGMP certification for key products, building microbiome CDMO facilities, and developing new drugs for conditions such as Alzheimer's. Chong Kun Dang Bio was established in 2001 and is headquartered in Seodaemun-gu, Seoul.